Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lexicon Pharmaceuticals (LXRX) Current Deferred Revenue (2025)

Lexicon Pharmaceuticals (LXRX) has disclosed Current Deferred Revenue for 4 consecutive years, with $4.3 million as the latest value for Q3 2025.

  • On a quarterly basis, Current Deferred Revenue changed N/A to $4.3 million in Q3 2025 year-over-year; TTM through Sep 2025 was $4.3 million, a N/A change, with the full-year FY2011 number at $119000.0, down 44.39% from a year prior.
  • Current Deferred Revenue was $4.3 million for Q3 2025 at Lexicon Pharmaceuticals, down from $17.5 million in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $45.0 million in Q1 2025 to a low of $4.3 million in Q3 2025.